IVERIC bio Inc

IVERIC bio — Ophthotech — Investor Presentation (July 2017)

30 slides from IVERIC bio's investor presentation, Jul 26, 2017

  1. Slide 1: July 2017 Corporate Overview

    1 NASDAQ: OPHT July 2017 Corporate Overview

  2. Slide 2: Forward-looking statements

    2 Forward‐looking statements Any statements in this presentation about Ophthotech’s future expectations, plans and prospects constitute forward‐looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward‐looking statements include

  3. Slide 3: Strategic Objective

    3 Strategic Objective Science driven, retina focused company with multiple programs concentrated in orphan and age‐related indications

  4. Slide 4: Timeline/Planned Milestones on the Near Horizon

    4 Timeline/Planned Milestones on the Near Horizon 2017Set Strategic Plan  Stargardt Disease – Zimura Initiate program By end of this year  Wet AMD – Zimura Initiate Phase 2a trial By end of this year  IPCV – Zimura Initiate Phase 2a trial By end of this year  Dry AMD – Zimura Strategic decision

  5. Slide 5: Multiple Shots on Goal

    5 Multiple Shots on Goal Stargardt Disease (Orphan) Dry AMD (GA) Wet AMD Von Hippel‐Lindau Syndrome (Orphan) Intermediate/Posterior Uveitis (Orphan) Retinoblastoma (Orphan) Zimura (Complement C5 inhibitor) Fovista (anti‐PDGF) Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) • Plan to initiate pro

  6. Slide 6: Zimura, C5 Complement Inhibitor: Ophthalmic Orphan and Age-Related Eye Diseases

    6 Zimura, C5 Complement Inhibitor Ophthalmic Orphan and Age‐Related Eye Diseases

  7. Slide 7: Complement Pathway and Zimura inhibition

    7 C3 C3b C5 C4 C2 C3 C3 C3b C3b C4b C4b C3b C5b C5b C 8 C 9 C 9 C6 C7 Pathogen C3bC3b BbC2a C6‐C9 Factor H C1q C1r C1s CD46 CD46 Microbial Cell Surface AlternativeLectin Classical Zimura X X Pathogen Complement Pathway Source: OPHT internal Cell Death Membrane Attack Complex (MAC) X

  8. Slide 8: Zimura, C5 Complement Inhibitor: Stargardt Disease (Orphan Indication)

    8 Zimura, C5 Complement Inhibitor Stargardt Disease (Orphan Indication)

  9. Slide 9: Rationale for Development of Zimura in Stargardt

    9 • High unmet medical need – Estimated prevalence (US) of ~32,000 ‐ 41,000 patients(1) – No FDA approved treatment available • Scientific evidence(2) – Bisretinoids (visual cycle waste) activate complement – Complement inhibition rescues photoreceptor cells in a Stargardt animal model – Anti‐C5 imp

  10. Slide 10: OPHT Engages Foundation Fighting Blindness

    10 • OPHT entered into an agreement with Foundation Fighting Blindness (FFB) – Highly‐distinguished organization recognized for its scientific commitment to orphan inherited retinal diseases – Established network of scientists and a robust patient registry • OPHT gains access to FFB’s publicly avail

  11. Slide 11: Complement inhibition may lead to healthier RPE cells

    11 Gene Mutation: Waste Accumulation InflammationX Zimura® Complement inhibition may potentially lead to healthier RPE cells = Better ability to process and recycle the waste and therefore slow down the progression of Stargardt disease (1) Waste Accumulation Waste Accumulation Energy Production Wast

  12. Slide 12: Autosomal Recessive Stargardt Disease (STGD1): Disease Overview

    12 Progressive damage to the macula and retina caused by mutations in the ABCA4 gene • ABCA4 gene makes a protein that normally helps clear away vitamin A byproducts inside photoreceptors • Lack of the needed protein leads to the accumulation of bisretinoids/lipofuscin/A2E (“wear and tear” pigment:

  13. Slide 13: Complement Inhibition Rescues Light Perceiving Cells

    13 Complement Inhibition Rescues Light Perceiving Cells Expression of Complement Inhibitory Protein (CRRY) ~2 fold decrease in bisretinoid accumulation ~30% increase in the number of photoreceptor nuclei Normalized Complement Activity Source: Proc Natl Acad Sci U S A. 2017; 114(15):3987‐3992.

  14. Slide 14: Decreased Complement Activity: Rescued Photoreceptors

    14 Decreased Complement Activity: Rescued Photoreceptors AAV‐Null BALB/cAAV‐CRRY * 1 Year old Albino Abca4‐/‐or BALB/c Mice Source: Proc Natl Acad Sci U S A. 2017; 114(15):3987‐3992.

  15. Slide 15: Decreased Complement Activity: Decreased Lipofuscin Accumulation

    15 Decreased Complement Activity: Decreased Lipofuscin Accumulation AAV‐Null BALB/cAAV‐CRRY 1 Year old Albino Abca4‐/‐or BALB/c Mice Source: Proc Natl Acad Sci U S A. 2017; 114(15):3987‐3992.

  16. Slide 16: Waste + Complement Activation: Significant Reduction in RPE Viability

    16 Waste + Complement Activation: Significant Reduction in RPE Viability Complement ActivationWaste: all‐Trans‐Retinal (atRal) Expected Additive EffectatRal + Complement Combined Effect >> Expected Additive Effect Source: Invest Ophthalmol Vis Sci. 2013;54:2669‐2677

  17. Slide 17: Anti-C5 Inhibits atRal/Complement Induced Cell Toxicity

    17 Anti‐C5 Inhibits atRal/Complement Induced Cell Toxicity *P < 0.05 Source: Invest Ophthalmol Vis Sci. 2013;54:2669‐2677

  18. Slide 18: Zimura, C5 Complement Inhibitor: Wet and Dry Age-Related Macular Degeneration

    18 Zimura, C5 Complement Inhibitor Wet and Dry Age‐Related Macular Degeneration

  19. Slide 19: Rationale for Development of Zimura in Wet AMD

    19 • Unmet medical need – major market opportunity: – Anti‐VEGF monotherapy  Shown to reach a ceiling effect  Majority of patients do not reach a visual acuity of > 20/40  In the real world most patients lose vision over time • Patients receiving anti‐VEGF monotherapy may develop geographic atrop

  20. Slide 20: Zimura Phase 1/2a Wet AMD – Completed

    20 Zimura Phase 1/2a Wet AMD – Completed 46% 47% 60% 0% 15% 30% 45% 60% 0.3 mg 1.0 mg 2.0 mg n=13 n=15 n=15 Significant Visual Gain ≥ 3‐ETDRS Lines at Week 24 % P a t i e n t s • Inclusion: - Treatment Naïve subjects - All CNV subtypes • Design: - Six monthly doses of Zimura in combination with 0.5m

  21. Slide 21: Rationale for Development of Zimura in Dry AMD

    21 • An unmet medical need – major market opportunity • Phase 2/3 clinical trial of monotherapy Zimura is ongoing • Strategic decision based on the competitor’s study outcome available in the second half of 2017 Rationale for Development of Zimura in Dry AMD Geographic Atrophy, a disease characteriz

  22. Slide 22: Zimura, C5 Complement Inhibitor: Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

    22 Zimura, C5 Complement Inhibitor Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

  23. Slide 23: Rationale for Development of Zimura in IPCV

    23 • Unmet medical need – Estimated prevalence (U.S.) ~80,000 – 160,000 (1) • Scientific rationale (2) – Response to anti‐VEGF monotherapy may be limited – Anti‐VEGF treatment may lead to complement activation • Plan to initiate Phase 2a trial by the end of this year Rationale for Development of Zim

  24. Slide 24: Zimura, C5 Complement Inhibitor: Non-Infectious Intermediate/Posterior Uveitis

    24 Zimura, C5 Complement Inhibitor Non‐Infectious Intermediate/Posterior Uveitis (Orphan Indication)

  25. Slide 25: Rationale for Development of Zimura in Uveitis

    25 • Unmet medical need – Need for effective intermediate/posterior uveitis treatments with minimal local and systemic adverse events – Estimated total Uveitis prevalence (U.S.)*: 38 in 100,000, or about ~120,000 (1) • Scientific rationale (2) – Anti‐C5, sCRRY inhibits uveitis in Experimental Autoim

  26. Slide 26: Fovista, Anti-PDGF: Von Hippel-Lindau Syndrome and Retinoblastoma

    26 Fovista, Anti‐PDGF Von Hippel‐Lindau Syndrome (Orphan Indication) and Retinoblastoma (Orphan Indication)

  27. Slide 27: Rationale for Development of Fovista in Von Hippel-Lindau Syndrome

    27 • Unmet medical need – No optimal treatment option available – Estimated Prevalence (U.S.): ~7,000 (1) • Scientific rationale – PDGF and VEGF are involved in the proliferation of the capillary hemangioma (2) – Anti‐VEGF + anti‐PDGF combination therapy has the potential to slow down the progressio

  28. Slide 28: Rationale for Development of Fovista in Retinoblastoma

    28 • Unmet medical need – No optimal treatment for metastatic tumor – Potential to be first to market to prevent or decrease the likelihood of metastasis – Estimated Prevalence (U.S.): 1 out of every 20,000 births per year /200 new cases a year (1) • Scientific rationale – Retinoblastoma cell lines

  29. Slide 29: Investment highlights

    29 • Positioned to identify value driven solutions for ophthalmic diseases with significant unmet need • Orphan Ophthalmology (3 current or planned clinical programs, 1 planned pre‐clinical) led by a program for Stargardt Disease – Significant need to treat underserved patients with rare ophthalmic

  30. Slide 30: Timeline/Planned Milestones on the Near Horizon

    30 Timeline/Planned Milestones on the Near Horizon 2017Set Strategic Plan  Stargardt Disease – Zimura Initiate program By end of this year  Wet AMD – Zimura Initiate Phase 2a trial By end of this year  IPCV – Zimura Initiate Phase 2a trial By end of this year  Dry AMD – Zimura Strategic decisio

Ophthotech — Investor Presentation (July 2017) on 6ix